

Letter

Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate

Pierpaolo Di Micco ^{1,*}, Vincenzo Russo ²  and Corrado Lodigiani ³ 

¹ UOC Medicina, Fatebenefratelli Hospital of Naples, 34102 Naples, Italy

² Chair of Cardiology, Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”—Monaldi Hospital, Piazzale Ettore Ruggeri, 80131 Naples, Italy; v.p.russo@libero.it

³ Thrombosis and Hemorrhagic Center, Humanitas Research Hospital IRCC and Humanitas University, 20089 Rozzano, Italy; corrado.lodigiani@humanitas.it

* Correspondence: pdimicco@libero.it

Received: 18 August 2020; Accepted: 22 September 2020; Published: 27 September 2020



Abstract: As reported by the World Health Organization, a novel coronavirus (COVID-19) was identified as the causative virus of new viral pneumonia of unknown etiology by Chinese authorities on 7 January 2020. The virus was named COVID-19 and because of its ability to cause severe acute respiratory syndrome (i.e., SARS) this infection has also been defined as SARS-CoV2. Furthermore, an association between COVID-19 infection and venous thromboembolism has been reported in several series around the world. For this reason, methods used to improve diagnostic tools, pharmacological thromboprophylaxis and type of anticoagulants are discussed in this expert opinion.

Keywords: COVID-19; coronavirus; SARS-CoV2; venous thromboembolism

Human coronaviruses (HCoVs) are enveloped non-segmented positive-strand RNA viruses, with rapid evolution owing to their high genomic nucleotide substitution rates and recombination [1]. HCoVs are associated with multiple respiratory diseases of varying severity, including common cold, pneumonia and bronchiolitis. Severe Acute Respiratory Syndrome (SARS) in 2003 [2] and Middle East Respiratory Syndrome (MERS) in 2012 were respiratory infections with high mortality due to HCoVs (2). A highly pathogenic HCoV, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recognized in Wuhan, China, as the cause of the coronavirus disease 2019 (COVID-19) outbreak, with alarming morbidity and mortality [3]. Emerging worldwide clinical experiences testified that COVID-19 showed more lethal action than SARS and MERS [4], probably due to the concomitant alteration of haemostasis with a trend toward microthrombosis and venous thromboembolism (VTE).

Since early epidemiological reports, a hypercoagulable state characterized by increased levels of fibrinogen and D-dimer has been found in hospitalized COVID-19 patients [5–8]; moreover, an increased rate of pulmonary thrombi and emboli has been found in autopsical series [9], as also shown in other viral pandemics such as influenza A H1N1 [10]. Based on these data, clinical researchers focused their attention on life-threatening complications of the hypercoagulable state as pulmonary embolism (PE) or disseminated intravascular coagulation (DIC) [11]. In this way, different clotting abnormalities have been underlined in patients hospitalized for COVID-19 in the ICU compared to other wards, underlining that DIC is a serious complication for these patients that can be found early with frequent clotting tests [12]. For this reason, in the literature, some authors reported a positive experience with therapeutic doses of low molecular weight heparin in patients with severe COVID-19 reporting a reduction of mortality and mortality associated with DIC or PE [13].

The prevalence of PE in COVID-19 patients ranges from 15% to 40%; this large difference across clinical studies may be due to the size and heterogeneity of sample populations, presenting significant

differences in clinical characteristics, pre-admission pharmacological treatments and anticoagulation regimens used for VTE prophylaxis during the hospitalization [14–17]. Moreover, the timing and the methodology to perform VTE diagnosis are heterogeneous across different studies [18–20]. Similar counteracting data may be found for the clinical indication to perform thromboprophylaxis with low molecular weight heparin after discharge.

For this reason, the guidelines of the American College of Chest Physicians, in absence of a contraindication, recommend an anticoagulant thromboprophylaxis with low-molecular-weight heparin (LMWH) or fondaparinuxin for hospitalized COVID-19 patients. The routine ultrasound screening for the detection of asymptomatic deep vein thrombosis (DVT) has not suggested, however, clinicians should have a low threshold for performing ultrasound in patients with a reasonable degree of clinical suspicion for VTE [21]. The use of biomarkers in the diagnostic evaluation for suspected DVT or PE is not suggested. Therefore, an important keypoint is that routinely vascular diagnostics are not suggested because routine prophylaxis is useful and suggested per se during hospitalization for COVID-19. Furthermore, this daily clinical approach is also useful because the routine screening with vascular diagnostics may have misunderstandings in their application: it is still unclear the better time indicated to perform a vascular diagnostic useful to detect asymptomatic VTE in patients affected by COVID-19 (e.g., day 1, 3, 7 or 15 of hospitalization). Similar limitations may be found for symptomatic patients with overt PE: typical signs and symptoms of PE such as dyspnoea and chest pain are also present during COVID-19 per se due to viral and immunological lung injuries, and this similar clinical aspect is associated with the reduced clinical support given by biomarkers of suspected VTE as d-dimer and alkalosis on haemogasanalysis.

In conclusion, the role of vascular diagnostics for VTE diagnosis in symptomatic or asymptomatic inpatients affected by COVID-19 is still a matter of discussion and needs to be better evaluated as well as the better time to perform vascular diagnostics in order to confirm VTE with objective methods; on the other hand, the useful role of thromboprophylaxis is clear as well as the use of other anticoagulants before hospital admission, because they reduce the rate of VTE in this clinical setting.

Author Contributions: P.D.M. performed conceptualization of manuscript and Data Curation, C.L. and V.R. wrote review and Writing-Review & Editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lai, M.M.; Cavanagh, D. The molecular biology of coronaviruses. *Adv. Virus Res.* **1997**, *48*, 1–100. [[PubMed](#)]
2. De Wit, E.; van Doremalen, N.; Falzarano, D.; Munster, V.J. SARS and MERS: Recent insights into emerging coronaviruses. *Nat. Rev. Microbiol.* **2016**, *14*, 523–534. [[CrossRef](#)] [[PubMed](#)]
3. McCloskey, B.; Heymann, D.L. SARS to novel coronavirus: Old lessons and new lessons. *Epidemiol. Infect.* **2020**, *148*, e22. [[CrossRef](#)] [[PubMed](#)]
4. Mahase, E. Coronavirus: Covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. *BMJ* **2020**, *368*, m641. [[CrossRef](#)] [[PubMed](#)]
5. Poyiadji, N.; Cormier, P.; Patel, P.Y.; Hadied, M.O.; Bhargava, P.; Khanna, K.; Nadig, J.; Keimig, T.; Spizarny, D.; Reeser, N.; et al. Acute Pulmonary Embolism and COVID-19. *Radiology* **2020**, *297*, 201955. [[CrossRef](#)] [[PubMed](#)]
6. Di Micco, P.; Russo, V.; Carannante, N.; Imparato, M.; Rodolfi, S.; Cardillo, G.; Lodigiani, C. Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort. *J. Clin. Med.* **2020**, *9*, E1371. [[CrossRef](#)] [[PubMed](#)]
7. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* **2020**, *395*, 1054–1062. [[CrossRef](#)]

8. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J. Thromb. Haemost.* **2020**, *18*, 844–847. [\[CrossRef\]](#) [\[PubMed\]](#)
9. Wichmann, D.; Sperhake, J.P.; Lütgehetmann, M.; Steurer, S.; Edler, C.; Heinemann, A.; Heinrich, F.; Mushumba, H.; Kniep, I.; Schröder, A.S.; et al. Autopsy Findings and Venous Thromboembolism in Patients with COVID-19. *Ann. Intern. Med.* **2020**, M20-2003. [\[CrossRef\]](#) [\[PubMed\]](#)
10. Obi, A.T.; Tignanelli, C.J.; Jacobs, B.N.; Arya, S.; Park, P.K.; Wakefield, T.W.; Henke, P.K.; Napolitano, L. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. *J. Vasc. Surg. Venous Lymphat. Disord.* **2019**, *7*, 621. [\[CrossRef\]](#) [\[PubMed\]](#)
11. Fogarty, H.; Townsend, L.; Ni Cheallaigh, C.; Bergin, C.; Martin-Loeches, I.; Browne, P.; Bacon, C.L.; Gaule, R.; Gillett, A.; Byrne, M.; et al. COVID-19 coagulopathy in Caucasian patients. *Br. J. Haematol.* **2020**, *189*, 1044–1049. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Spiezia, L.; Boscolo, A.; Poletto, F.; Cerruti, L.; Tiberio, I.; Campello, E.; Navalesi, P.; Simioni, P. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. *Thromb. Haemost.* **2020**, *120*, 998–1000. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J. Thromb. Haemost.* **2020**, *18*, 1094–1099. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Lodigiani, C.; Iapichino, G.; Carenzo, L.; Cecconi, M.; Ferrazzi, P.; Sebastian, T.; Kucher, N.; Studt, J.-D.; Sacco, C.; Alexia, B.; et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb. Res.* **2020**, *191*, 9–14. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Klok, F.A.; Kruip, M.; Van Der Meer, N.; Arbous, M.; Gommers, D.; Kant, K.; Kaptein, F.; Van Paassen, J.; Stals, M.; Huisman, M.; et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. *Thromb. Res.* **2020**, *191*, 148–150. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Klok, F.A.; Kruip, M.; Van Der Meer, N.; Arbous, M.; Gommers, D.; Kant, K.; Kaptein, F.; Van Paassen, J.; Stals, M.; Huisman, M.; et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb. Res.* **2020**, *191*, 145–147. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Cui, S.; Chen, S.; Li, X.; Liu, S.; Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J. Thromb. Haemost.* **2020**, *18*, 1421–1424. [\[CrossRef\]](#) [\[PubMed\]](#)
18. Russo, V.; Di Maio, M.; Attena, E.; Silverio, A.; Scudiero, F.; Celentani, D.; Lodigiani, C.; Di Micco, P. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. *Pharmacol. Res.* **2020**, *159*, 104965. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Cattaneo, M.; Morici, N. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new “prudent” randomised clinical trial. *Blood Transfus.* **2020**, *18*, 237–238. [\[PubMed\]](#)
20. Marietta, M.; Tripodi, A. Rebuttal to letter “Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new “prudent” randomised clinical trial”. *Blood Transfus.* **2020**, *18*, 239–240. [\[PubMed\]](#)
21. COVID-19 Updates to CHEST Anticoagulation Guidelines. Available online: <https://www.chestnet.org/-/media/chestnetorg/Guidelines-and-Resources/Documents/CHEST-Anticoagulation.ashx?la=en&hash=97AAA1CCD88F7023D344E1E6F3EFBC2D63653714> (accessed on 18 August 2020).

